参麦注射液对COPD合并肺结核患者细胞因子及ESAT-6/CFP-10水平的影响  

Effect of Shenmai injection on cytokines and ESAT-6/CFP-10 levels in patients with COPD with pulmonary tuberculosis

作　　者：李丹剑[1] 王勇[1] 彭春仙[2] 

机构地区：[1]浙江省常山县人民医院内一科,浙江衢州324200 [2]衢州市人民医院内一科,浙江衢州324003

出　　处：《中国生化药物杂志》2017年第5期145-148,共4页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨参麦注射液对慢性阻塞性肺疾病（COPD）合并肺结核患者细胞因子及ESAT-6/CFP-10水平的影响。方法选取本院呼吸科收治的COPD合并肺结核患者158例,按随机数字表法分组,对照组79例予以常规治疗,研究组79例在对照组基础上予以参麦注射液治疗,观察并记录2组间血清ESAT-6蛋白、CFP-10蛋白、IFN-γ水平、细胞因子水平、外周血免疫细胞水平,同时比较临床疗效及病灶吸收有效率。结果对照组临床总有效率（84.81%）低于研究组临床总有效率（94.94%）,差异具有统计学意义（P〈0.05）;对照组病灶吸收有效率（87.33%）低于研究组病灶吸收有效率（96.21%）,差异具有统计学意义（P〈0.05）;与对照组比较,研究组治疗后血清ESAT-6蛋白、CFP-10蛋白、IFN-γ水平较低,治疗后血清TNF-α、IL-6、s IL-2R水平较低,治疗后外周血NK细胞、CD4~＋T淋巴细胞及CD4~＋/CD8~＋水平较高,CD8~＋T淋巴细胞水平较低,差异均具有统计学意义（P〈0.05）。结论参麦注射液能够明显降低COPD合并肺结核患者血清TNF-α、IL-6、s IL-2R及ESAT-6/CFP-10水平,改善细胞免疫功能,有效促进病灶吸收,提高临床疗效。Objective To investigate the effect of Shenmai injection on cytokines and ESAT-6/CFP-10 levels in patients with Chronic obstructive pulmonary disease（COPD）with pulmonary tuberculosis.Methods158 patients with COPD with pulmonary tuberculosis from the Department of Respiratory in our hospital were selected and divided into 2 groups, 79 cases in the control group treated with routine treatment, 79 cases in the experiment group treated with Shenmai injection on the basis of the control group, levels of neurotransmitters in the brain, serum ESAT-6 protein, CFP-10 protein, IFN-γ levels, cytokine levels, peripheral blood immune cell levels, and the clinical effect and the focus absorption efficiency were compared after the treatment.ResultsThe clinical total effective rate in the control group（84.81%）was lower than that in the experiment group（94.94%）, with significant difference （P〈0.05）;the focus absorption efficiency in the control group（87.33%）was lower than that in the experiment group（96.21%）, with significant difference （P〈0.05）;compared with the control group, serum ESAT-6 protein、 CFP-10 protein、IFN-γ levels were lower after treatment in the experiment group, the serum levels of TNF-α、IL-6、sIL-2R were lower, peripheral blood levels of NK cells, CD4＋T lymphocytes and CD4＋/CD8＋ were higher, peripheral blood level of CD8＋T lymphocytes was lower, with significant difference （P〈0.05）.ConclusionShenmai injection can significantly reduce the serum levels of TNF-α、IL-6、sIL-2R and ESAT-6/CFP-10 in patients with COPD with pulmonary tuberculosis, improve cellular immune function, promote the absorption of lesions effectively,and improve clinical efficacy.

关 键 词：COPD合并肺结核 参麦注射液 细胞因子 ESAT-6/CFP-10 

分 类 号：R563.9[医药卫生—呼吸系统]